Assembly Biosciences (ASMB) Hits New 12-Month Low at $13.13

Shares of Assembly Biosciences Inc (NASDAQ:ASMB) hit a new 52-week low on Monday . The stock traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares trading hands. The stock had previously closed at $18.79.

Several analysts have recently weighed in on the stock. BidaskClub upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Chardan Capital reiterated a “hold” rating and set a $30.00 target price on shares of Assembly Biosciences in a research report on Monday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $43.00.

The stock has a market cap of $415.44 million, a P/E ratio of -4.09 and a beta of 1.75.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). The firm had revenue of $3.74 million during the quarter, compared to analyst estimates of $3.69 million. Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. As a group, sell-side analysts expect that Assembly Biosciences Inc will post -4.61 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Valeo Financial Advisors LLC boosted its position in Assembly Biosciences by 0.5% in the first quarter. Valeo Financial Advisors LLC now owns 201,000 shares of the biopharmaceutical company’s stock valued at $3,958,000 after buying an additional 1,000 shares in the last quarter. Tibra Equities Europe Ltd acquired a new position in Assembly Biosciences in the first quarter valued at about $918,000. Deutsche Bank AG boosted its position in Assembly Biosciences by 29.8% in the fourth quarter. Deutsche Bank AG now owns 54,606 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 12,525 shares in the last quarter. Capital Impact Advisors LLC boosted its position in Assembly Biosciences by 46.6% in the fourth quarter. Capital Impact Advisors LLC now owns 68,875 shares of the biopharmaceutical company’s stock valued at $1,524,000 after buying an additional 21,887 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Assembly Biosciences by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 228,069 shares of the biopharmaceutical company’s stock valued at $5,158,000 after buying an additional 12,055 shares in the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Assembly Biosciences (ASMB) Hits New 12-Month Low at $13.13” was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.thestockobserver.com/2019/04/17/assembly-biosciences-asmb-hits-new-12-month-low-at-13-13.html.

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

See Also: How do taxes affect a CDs total return?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.